Macular News

AAO 2017: Tom Perski

Low Vision Aid Utilizing VR Technology and the Unique Features of Iris Vision http://www.irisvision.com

AAO 2017: Charles Wykoff MD PhD

Charles C. Wykoff, MD, PhD Retina Consultants Houston — New Approaches to Managing Wet Macular Degeneration. Plus, Results of the 6 – Month Prospective, Phase 1/2 HULK Study Regarding Diabetic Macular Edema

AAO 2017: Press Conference

Latest on Gene Therapy and Stem Cell Therapy for Retinal Diseases (Note: Poor Audio) — AAO 2017 Press Conference Nov. 13, 2017 Stephen R. Russell, M.D., University of Iowa Health Care Irene Maumenee, M.D, 2017 Academy Laurate recipient Ninel Z. Gregori, M.D., Bascom Palmer Eye Institute Eyal Banin, M.D., Ph.D …

AAO 2017: Richard Rosen MD

Richard Rosen MD New York Eye and Ear Infirmary of Mount Sinai — Early Diagnosis of Diabetic Retinopathy using OCT Angiography

AAO 2017: Mr Rob Nevin

Rob Nevin – BlindSquare GPS IOS App for blind and low vision navigation

AAO 2017: Pravin Dugel MD

Pravin U Dugel, MD Retinal Associates of Arizona — HAWK & HARRIER: 48–week Results Of 2 Multi-Centered, Randomized, Double-Masked Trials of Brolucizumab Versus Aflibercept For Neovascular AMD and promising future treatments

AAO 2017: John Shepherd MD

John Shepherd, MD The Weigel Williamson Center for Visual Rehabilitation University Nebraska Medical Center — Why should I Consult a Low Vision Specialist?

AAO 2017: David Boyer MD

David Boyer, MD Retina-Vitreous Specialists Medical Group — Emerging Dry Macular Degeneration Treatments

AAO 2017: Ron Gentile MD

Dr. Ron Gentile, MD, FACS, FASRS New York Eye and Ear of Mount Sinai Patient Satisfaction and expectations

AAO 2017: Joe Fontenot MD

Dr. Joe Fontenot, MD, CLVT Community Service for Vision Rehabilitation http://www.csvrlowvision.org Low vision technology

AAO 2017: Mark Gillies MD, PhD

University Sydney Australia Macular Research Group, Save Sight Institute Treatment Patterns and visual outcomes for AMD

ARVO 2017: Audrey Voisin

University of Poitiers – Poitiers, France Using IPS Cells to Develop Molecular Therapy for AMD

ARVO 2017: Feriel Presswalla

University of Michigan Kellogg Eye Center Automated Quantification of Subcellular Structures in the RPE: Lipid Droplets, Autophagic Vacuoles, and Lipofuscin

ARVO 2017: Kapil Bharti PhD

Induced stem cells, RPE cells and translational applications for degenerative eye diseases.

ARVO 2017: Deborah Ferrington PhD

Research into mitochondria function and protein degradation in macular degeneration.

ARVO: 2017: Paul Baird Phd

Looking at molecular reason for non-response in Anti-VEGF treatment

ARVO 2017: Jim Handa MD

Identifying pathways that induce vision loss as a consequence of drusen in Age Related Macular Degeneration

ARVO 2017: Alan Marmorstein, PhD

Explaining Clinical Trials, Requirements, procedure and efficacy for participation.

ARVO 2017: Alan Marmorstein, PhD

Understanding underlying mechanisms of degenerative diseases

ARVO 2017: Jack Sullivan, MD, PhD

Jack Sullivan, MD, PhD Development of gene-based therapeutics for retinal and macular degeneration

ARVO 2017: Ed Boyden, PhD

Ed Boyden, PhD Optogenetics – a method for manipulating the activity of nerve cells using light and cell mapping

Harvard 2016: Margaret DeAngelis PhD

Moran Eye Center University of Utah School of Medicine Genome-Wide Analysis of Allele Specific Expression Demonstrates the Role of Lipid Metabolism in AMD

Harvard 2016: Joshua Dunaief MD

Perelman Medical School University of Pennsylvania Roles of iron overload and oxidative stress in the blinding disease age-related macular degeneration